

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**PuraPharm**

**PURAPHARM CORPORATION LIMITED**

**培力農本方有限公司**

*(Formerly known as 培力控股有限公司 in Chinese)*

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 1498)**

**CHANGE OF HEADQUARTER AND  
PRINCIPAL PLACE OF BUSINESS IN HONG KONG**

The board (the “**Board**”) of directors (the “**Director(s)**”) of PuraPharm Corporation Limited (the “**Company**”) is pleased to announce that, with effect from 16 December 2021, the Company’s headquarter and principal place of business in Hong Kong has been changed to Unit 201–207, 2/F, Wireless Centre, Phase One, Hong Kong Science Park, Tai Po, New Territories, Hong Kong. The telephone number, facsimile number and website address of the Company remain unchanged.

By Order of the Board  
**PuraPharm Corporation Limited**  
**Chan Yu Ling, Abraham**  
*Chairman*

Hong Kong, 16 December 2021

*As at the date of this announcement, the executive Directors are Mr. Chan Yu Ling, Abraham, Ms. Man Yee Wai, Viola and Dr. Norimoto Hisayoshi; the non-executive Directors are Mr. Chow, Stanley and Mr. Cheong Shin Keong; and the independent non-executive Directors are Mr. Ho Kwok Wah, George, Dr. Leung Lim Kin, Simon and Prof. Tsui Lap Chee.*